Open AccessPhase I Clinical Evaluation of Carboplatin in Tumor‐Bearing Cats: A Veterinary Cooperative Oncology Group Study
Author(s) -
Kisseberth W.C.,
Vail D.M.,
Yaissle J.,
Jeglum K.A.,
Couto C.G.,
Ward H.,
Khanna C.,
Obradovich J. E.
Publication year - 2008
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.2007.0017.x
Subject(s) - carboplatin , medicine , cats , neutropenia , hemangiosarcoma , chemotherapy , surgery , cisplatin , angiosarcoma
Background: The dosage of carboplatin in cats has been reported anecdotally and experimentally in non‐tumor‐bearing cats, but the dosage for carboplatin treatment in tumor‐bearing cats has yet to be defined in a prospective clinical trial. Purpose: To determine the maximally tolerated dose (MTD) and dose‐limiting toxicosis (DLT) of carboplatin in tumor‐bearing cats. Cats: Fifty‐nine cats with measurable solid tumors. Methods: The starting dose of carboplatin was 160 mg/m 2 of body surface area IV. Doses were increased by 20 mg/m 2 in cohorts of 3–14 cats until the MTD was reached. Results: The 59 cats entered into this multi‐institutional phase I study received 1 or more doses of carboplatin at various dosages and were evaluated for toxicity, response to treatment, or both. The MTD was 240 mg/m 2 and neutropenia was the DLT. For the 1st cycle of treatment in 44 cats evaluated for neutropenia, 6 episodes of grade 3 or greater neutropenia occurred on days 7 (n=1), 14 (n=4), and 21 (n=1). There was no evidence of drug‐induced nephrotoxicosis or pulmonary edema. Preliminary evidence of antitumor activity was observed in 7 of 59 (11.9%; 95% CI, 5.6–22.8%) cats evaluated for response to treatment. There was 1 complete response (cutaneous hemangiosarcoma) and 6 partial responses (4 injection site sarcomas, 1 oral squamous cell carcinoma, 1 lymphoma). Responses were of short duration (median, 42 days; range, 7–168 days). Conclusions and Clinical Importance: The dose of carboplatin recommended to treat tumor‐bearing cats is 240 mg/m 2 IV every 3–4 weeks.